#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Dermatitis atopic Dementia Alzheimer's type Asthma Type 2 diabetes mellitus Breast cancer metastatic Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    ROHHAD syndrome Necrotising myositis Erdheim-Chester disease Acute myeloid leukaemia (in remission) Familial amyotrophic lateral sclerosis Adult T-cell lymphoma/leukaemia refractory Subarachnoid haemorrhage Complex regional pain syndrome Depression Porphyria non-acute Myxofibrosarcoma Acute myeloid leukaemia recurrent Hepatoblastoma Toxic epidermal necrolysis Microvillous inclusion disease More trials…

    Learn about Rare Diseases

    Breast angiosarcoma metastatic Synovial sarcoma metastatic – Diagnostics Castleman’s disease – Basic Information Hereditary angioedema – Life with Disease Prader-Willi syndrome Metachromatic leukodystrophy – Diagnostics Familial haemophagocytic lymphohistiocytosis – Diagnostics KBG syndrome – Trials in Disease Gaucher’s disease type III – Treatment SAPHO syndrome – Basic Information More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    LTX-002 SODIUM Bisoprolol Colecalciferol Mometasone Furoate Ph. Eur. Trametinib Gadobenate Dimeglumine Img-007 Povidone Fenoterol Hydrobromide Poloxamer 407 Cibotercept Surzebiclimab VX-407 Tipapkinogene Sovacivec Pasireotide Diaspartate GLYCYL-TYROSINE Op-1250 Benzylpenicillin Obeticholic Acid Human Coagulation Factor Viii More therapies…

    Learn about Your Condition

    Fibrosarcoma Exfoliation glaucoma Behcet's syndrome Thyroid cancer Peripheral ischaemia Delayed graft function Proteinuria Lung transplant rejection Pain Abdominal wall pain Tympanic membrane perforation Anogenital warts Hypervolaemia Lysosomal storage disorder Seasonal allergy More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Sørlandet sykehus Kristiansand

Sørlandet sykehus Kristiansand

Egsveien 100, Kristiansand, 4615, Norway

Want to learn more about this study or check if you can participate? Contact us.

  • Rinatabart Sesutecan plus Bevacizumab vs standard care as maintenance for recurrent platinum‑sensitive ovarian cancer after second‑line chemotherapy

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • HUMAN IGG1 KAPPA MONOCLONAL ANTIBODY AGAINST FOLR1 CONJUGATED TO 1-[(2R,3R,4R,5S,52S)-1,2,3,4,5-PENTAHYDROXY-52-{[(2S)-1-{[(2S)-5-CARBAMOYLAMINO-1-OXO-1-{3-[({[(1S,9S)-9-ETHYL-5-FLUORO-9-HYDROXY-4-METHYL10,13-DIOXO-2,3,9,10,13,15-HEXAHYDRO-1H,12HBENZO[DE]PYRANO[3′,4′:6,7]INDOLIZINO[1,2-B]QUINOLIN-1-YL]CARBAMOYL}OXY)METHYL]ANILINO}PENTAN-2-YL]AMINO}-3-METHYL-1-OXOBUTAN-2-YL]CARBAMOYL}-7-[(2S,3R,4R,5R)-2,3,4,5,6-PENTAHYDROXYHEXYL]-46,54-DIOXO10,13,16,19,22,25,28,31,34,37,40,43-DODECAOXA-7,47,53-TRIAZANONAPENTACONTAN-59-YL]-2,5-DIOXOPYRROLIDIN-3-YL
    • Bevacizumab
    Austria Belgium Czechia Denmark Finland France +6

  • A double‑blind, placebo‑controlled trial of oral BI 1015550 in patients with systemic sclerosis

    Recruiting

    3 1
    Investigated Drugs:
    • Bi 1015550
    • 1-[[(5R)-2-[4-(5-Chloro-2-Pyrimidinyl)-1-Piperidinyl]-6,7- Dihydro-5-Oxidothieno[3,2-D]Pyrimidin-4- Yl]Amino]-Cyclobutanemethanol
    Austria Belgium Bulgaria Croatia Czechia Denmark +15

  • Ticagrelor, Acetylsalicylic Acid and Prasugrel in Patients with Acute Coronary Syndrome: A Study of Antiplatelet Management

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Myocardial ischaemia
    Investigated Drugs:
    • Dipyridamole
    • Prasugrel Hydrobromide
    • Ticagrelor
    Norway Spain

  • Study of lunsekimig versus placebo in adults with inadequately controlled eosinophilic COPD

    Recruiting

    4 1
    Investigated Drugs:
    • LUNSEKIMIG
    Czechia Germany Greece Lithuania The Netherlands Norway +4

  • A study of sacituzumab tirumotecan and bevacizumab in patients with newly diagnosed advanced ovarian cancer following first-line platinum-based chemotherapy

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Ovarian cancer
    Investigated Drugs:
    • Bevacizumab
    • Sacituzumab Tirumotecan
    Austria Belgium Czechia Denmark Finland France +9

  • A Study of Visugromab Compared to Placebo in Patients with Cancer-Related Cachexia to Test How Well It Works and How Safe It Is

    Recruiting

    4 1
    Investigated Diseases:
    • Cachexia
    Investigated Drugs:
    • VISUGROMAB
    Bulgaria Czechia France Germany Ireland Italy +5

  • Study of vicadrostat and empagliflozin combination in patients with type 2 diabetes, high blood pressure and cardiovascular disease

    Recruiting

    3 1 1
    Investigated Diseases:
    • Cardiovascular disorder
    • Type 2 diabetes mellitus
    • Hypertension
    Investigated Drugs:
    • Bi 690517
    • Empagliflozin
    Austria Belgium Bulgaria Croatia Czechia Denmark +17

  • Study on Ferric Derisomaltose for Patients with Iron Deficiency and Chronic Heart Failure

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Ferric Derisomaltose
    Bulgaria Croatia Czechia Denmark Hungary Latvia +6

  • Study of Ifinatamab Deruxtecan and Chemotherapy for Patients with Advanced or Metastatic Esophageal Squamous Cell Carcinoma

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Oesophageal squamous cell carcinoma
    Investigated Drugs:
    • Ifinatamab Deruxtecan
    • Docetaxel
    • Irinotecan Hydrochloride
    Belgium Denmark France Germany Italy The Netherlands +5

  • Study on Reducing Chronic Migraine Days with CGRP Antibodies and Botulinum Toxin A in Adults Aged 18-70

    Recruiting

    3 1 1
    Investigated Diseases:
    • Migraine
    Investigated Drugs:
    • Fremanezumab
    • Galcanezumab
    • Botulinum Toxin Type A
    Norway
1 2 3 … 5
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!